A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors
Interventions: DRUG: LCB84|DRUG: Anti-PD-1 monoclonal antibody
Sponsor: LegoChem Biosciences, Inc
Collaborators: AntibodyChem Biosciences, Inc.